ArticleBreast cancer (Dove Medical Press)2025
IDO1, IL4I1: Novel Immune Checkpoints in Breast Cancer Tumor-Associated Macrophages.
Article in Breast cancer (Dove Medical Press), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Increasing evidence supports the critical role of immune cell infiltration in breast cancer progression. Tumor-associated macrophages (TAMs) undergo metabolic reprogramming during polarization, which is vital for immune responses. Here, we screened for genes associated with TAMs infiltration and involved in tumor metabolism, and investigated their expression and effects in breast cancer. Patients and Methods: Bioinformatics analysis was used to screen genes related to immune cell infiltration and involved in tumor metabolism. Immunohistochemistry (IHC) was performed to validate the expression of selected target genes. Multiplex immunohistochemistry (mIHC) was applied to investigate the localization and expression relationship between target genes and TAMs. Real-time quantitative PCR (qRT-PCR) was used to detect the expression of target genes in TAMs. The Human Protein Atlas was utilized for single-cell clustering analysis of breast cancer to assess the expression patterns of target genes, while also evaluating the correlation between target genes and immune checkpoint expression. Results: Database analysis revealed that Indoleamine2,3-Dioxygenase1 (IDO1) and Interleukin 4 Induced 1 (IL4I1) are highly expressed in breast cancer, with their expression closely associated with immune cell infiltration, particularly macrophage infiltration, which exhibited the highest infiltration rate. IHC analysis revealed that both IDO1 and IL4I1 were expressed in breast cancer, which were mostly located in TAMs. mIHC co-localization demonstrated that IDO1 and IL4I1 were both expressed in TAMs, and qRT-PCR results confirmed increased expression of IDO1 and IL4I1 in TAMs. Single-cell analysis of breast cancer revealed that IDO1 and IL4I1 were most highly expressed in c-19 macrophages, and their expression was positively correlated with most immune checkpoints. Conclusion: This study suggests that IDO1 and IL4I1, which are involved in tumor metabolism, may play an important role in regulating TAMs immune infiltration in breast cancer. Therefore, IDO1 and IL4I1 are potential therapeutic targets for breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.